Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has received a consensus rating of “Hold” from the eight analysts that are presently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $26.75.

A number of equities analysts have issued reports on the stock. Canaccord Genuity set a $47.00 price objective on shares of Atara Biotherapeutics and gave the company a “buy” rating in a research note on Monday, August 7th. BidaskClub cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. ValuEngine cut shares of Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $20.00 price objective on shares of Atara Biotherapeutics in a research note on Friday, October 6th. Finally, Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating and set a $15.00 price objective on the stock in a research note on Tuesday, August 22nd.

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 4,400 shares of the stock in a transaction on Friday, October 27th. The shares were sold at an average price of $13.59, for a total value of $59,796.00. Following the sale, the chief executive officer now directly owns 737,767 shares in the company, valued at $10,026,253.53. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Isaac E. Ciechanover sold 2,200 shares of the stock in a transaction on Wednesday, October 11th. The stock was sold at an average price of $15.25, for a total transaction of $33,550.00. Following the completion of the sale, the chief executive officer now owns 737,767 shares in the company, valued at $11,250,946.75. The disclosure for this sale can be found here. Over the last quarter, insiders sold 56,609 shares of company stock worth $828,405. Company insiders own 16.20% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. raised its holdings in Atara Biotherapeutics by 617.9% in the first quarter. Goldman Sachs Group Inc. now owns 201,214 shares of the biotechnology company’s stock worth $4,135,000 after purchasing an additional 173,184 shares during the period. American International Group Inc. raised its holdings in Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after purchasing an additional 948 shares during the period. Schwab Charles Investment Management Inc. raised its holdings in Atara Biotherapeutics by 5.9% in the first quarter. Schwab Charles Investment Management Inc. now owns 79,580 shares of the biotechnology company’s stock worth $1,636,000 after purchasing an additional 4,446 shares during the period. Vanguard Group Inc. raised its holdings in Atara Biotherapeutics by 10.9% in the first quarter. Vanguard Group Inc. now owns 831,925 shares of the biotechnology company’s stock worth $17,095,000 after purchasing an additional 81,634 shares during the period. Finally, Wells Fargo & Company MN raised its holdings in Atara Biotherapeutics by 9.0% in the first quarter. Wells Fargo & Company MN now owns 58,252 shares of the biotechnology company’s stock worth $1,197,000 after purchasing an additional 4,791 shares during the period. Institutional investors own 82.74% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Atara Biotherapeutics, Inc. (ATRA) Given Average Rating of “Hold” by Brokerages” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/atara-biotherapeutics-inc-atra-given-average-rating-of-hold-by-brokerages/1676471.html.

Atara Biotherapeutics (NASDAQ:ATRA) traded up $1.45 during mid-day trading on Friday, reaching $15.55. 138,857 shares of the company were exchanged, compared to its average volume of 157,980.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.05). equities research analysts expect that Atara Biotherapeutics will post -3.99 EPS for the current year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.